Advanced cancer and life-limiting chronic nonmalignant diseases are associated with a number of hematological problems. Anemia and coagulation disorders, principally venous thrombosis and thrombocytopenia, are most commonly observed. Patients undergoing chemotherapy and bone marrow transplant have unique problems that include neutropenias and chemotherapy-induced drug toxicities, which will not be covered in this article.
Mercadante S, Gebbia V, Marrazzo A, et al.: Anaemia in cancer: Pathophysiology and treatment. Cancer Treat Rev. 2000; 26(4): 303-311.
2.
Groopman JE, Itri LM: Chemotherapy-induced anemia in adults: Incidence and treatment. J Natl Cancer Inst. 1999; 91(19): 1616-1634.
3.
Ludwig H, Strasser K: Symptomatology of anemia. Sem Oncol. 2001; 28(2 suppl. 8): 7-14.
4.
Groopman JE: Fatigue in cancer and HIV/AIDS. Oncology. 1998; 12(3): 335-344.
5.
Caro JJ, Salas M, Ward A, et al.: Anemia as an independent prognostic factor for survival in patients with cancer: A systemic, quantitative review. Cancer. 2001; 91(12): 2214-2221.
6.
Henke M: Correction of cancer anemia—impact on disease course, prognosis, and treatment efficacy, particularly for patients undergoing radiotherapy. Onkologie. 2001; 24(5): 450-454.
7.
Ferme C, Bastion Y, Brice P, et al.: Prognosis of patients with advanced Hodgkin’s disease: Evaluation of four prognostic models using 344 patients included in the Group d’Etudes des Lymphomes de I’Adulte study. Cancer. 1997; 80(6): 1124-1133.
8.
Obermair A, Cheuk R, Horwood K, et al.: Impact of hemoglobin levels before and during concurrent chemoradiotherapy on the response of treatment in patients with cervical carcinoma: Preliminary results. Cancer. 2001; 92(4): 903-908.
9.
Spivak JL: The blood in systemic disorders. Lancet. 2000; 355(9216): 1707-1712.
10.
Braczkowski R, Romanawsky W, Danikiewicz A, et al.: Decrease of erythropoietin level by human recombinant tumour necrosis factor alpha (hrec TNFalpha) in patients with advanced cancer. J Biol Regul Homeost Agents. 2001; 15(4): 366-369.
11.
Ludwig H, Fritz E, Leitgeb C, et al.: Prediction of response to erythropoietin treatment in chronic anemia of cancer. Blood. 1994; 84(4): 1056-1063.
12.
Weiss G: Pathogenesis and treatment of anaemia of chronic disease. Blood Rev. 2002; 16(2): 87-96.
13.
Ozguroglu M, Arun B, Demir G, et al.: Serum erythropoietin level in anemic cancer patients. Med Oncol. 2000; 17(1): 29-34.
14.
Charuruks N, Voravud N, Limpanasithikul W: Ratio of baseline erythropoietin (EPO) level and corrected reticulocyte count as an indicator for a favourable response to recombinant human erythropoietin (rhEPO) therapy in anaemic cancer patients. J Clin Lab Anal. 2001; 15(5): 260-266.
15.
Adamson JW, Ludwig H: Predicting the hematopoietic response to recombinant human erythropoietin (Epoetin alfa) in the treatment of the anemia of cancer. Oncology. 1999; 56(1): 46-53.
16.
Lastiri JM, Specterman SR, Rendo P, et al.: Predictive response variables to recombinant human erythropoietin treatment in patients with anemia and cancer. Medicina. 2002; 62(1): 41-47.
17.
Mock V, Atkinson A, Barsevick A, et al.: National Comprehensive Cancer Network Practice Guidelines for cancer related fatigue. Oncology. 2000; 14(11A): 151-161.
18.
Rossi EC: Red cell transfusion therapy in chronic anemia. Hematol Oncol Clin North Am. 1994; 8(6): 1045-1052.
19.
Johnston E, Crawford J: The hematologic support of the cancer patient. In Ann Berger (ed.): Principles and Practice of Supportive Oncology. Philadelphia: Lippincott-Raven, 1998.
20.
Abels RI, Larholt KM, Krantz JD, et al.: Recombinant human erythropoietin (rHuEPO) for the treatment of the anemia of cancer. Oncologist. 1996; 1(3): 140-150.
21.
Seidenfeld J, Piper M, Flamm C, et al.: Epoetin treatment of anemia associated with cancer therapy: A systematic review and meta-analysis of controlled clinical trial. J Natl Cancer Inst. 2001; 93(16): 1204-1214.
22.
Spaeth D, Marchal C, Bataillard A, et al.: Updating 1999 of Standards, Options and Recommendations (SOR) for the clinical use of erythropoietin in oncology. Federation of the French Center Centres (FNCLCC). Bull Cancer. 1999; 86(7-8): 631-639.
23.
Ludwig H, Rai K, Blade J, et al.: Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations. Hematol J. 2002; 3(3): 121-130.
24.
Hettiarachchi RJ, Lok J, Prins MH, et al.: Undiagnosed malignancy in patients with deep vein thrombosis: Incidence, risk indicators, and diagnosis. Cancer. 1998; 83(1): 180-185.
25.
Rance A, Emmerich J, Oger E, et al.: Venous thromboembolic disease and occult cancers: What investigations should be done? Apropos of 204 patients. Arch Mal Coeur Vaiss. 1997; 90(2): 209-214.
26.
Chraibi S, Bennis A, Kemmou O, et al.: Deep vein thromboses and occult cancers. Ann Cardiol Angeiol. 1997; 46(3): 145-149.
27.
Green KB, Silverstein RL: Hypercoagulability in cancer. Hematol Oncol Clin North Am. 1996; 10(2): 499-530.
28.
Luzzatto G, Schafer AI: The prethrombotic state in cancer. Semin Oncol. 1990, 17(2): 147-159.
29.
Lee AY, Levine MN.The thrombophilic state induced by therapeutic agents in the cancer patient. Seminars in Thrombosis & Hemostasis. 1999, 25(2): 137-145.
30.
Rickles FR, Levine M, Edwards RL: Hemostatic alternations in cancer patients. Cancer Metastasis Rev. 1992; 11(3-4): 237-248.
31.
Durica SS: Venous thromboembolism in the cancer patient. Curr Opin Hematol. 1997; 4:306-311.
32.
Thomas RH: Hypercoagulability syndromes. Arch Intern Med. 2001; 161(20): 2433-2439.
33.
Sorensen HT, Mellemkjaer L, Olsen JH, et. al.: Prognosis of cancers associated with venous thrombosis. N Engl J Med. 2000; 343(25): 1846-1850.
34.
Rickles FR, Edwards RL: Activation of blood coagulation in cancer: Trousseau’s syndrome revisted. Blood. 1983; 62(1): 14-31.
35.
Falanga A, Rickles FR: Pathophysiology of the thrombophilic state in the cancer patient. Semin Thromb Hemost. 1999; 25(2): 173-182.
36.
Rickles FR, Falanga A: Molecular basis for the relationship between thrombosis and cancer. Thromb Res. 2001; 102(6): V215-V224.
Iversen N, Lindhal AK, Alildgaard U: Elevated TFPI in management of malignant disease: relation to cancer type and hypercoagulation. Br J Haematol. 1998; 102(4): 889-895.
39.
Haim N, Lanir N, Hoffman R, et al.: Acquired activated protein C resistance is common in cancer patients and is associated with venous thromboembolism. Am J Med. 2001; 110(2): 91-96.
40.
Rogers JS, Murgo AJ, Fontana JA, et al.: Chemotherapy for breast cancer decreases plasma protein C and protein S. J Clin Oncol. 1988; 6:276-281.
41.
Kearon CMB, Ginsberg JS, Hirsh J: The role of venous ultrasonography in the diagnosis of suspected deep venous thrombosis and pulmonary embolism. Ann Intern Med. 1998; 129(12): 1044-1049.
42.
Lee AYY, Levine MN: Management of venous thromboembolism in cancer patients. Oncology. 2000; 14(3): 409-426.
43.
Lee AYY, Julian JA, Levin MN: Clinical utility of a rapid whole-blood d-Dimer assay in patients with cancer who present with suspected acute deep venous thrombosis. Ann Intern Med. 1999; 131(6): 417-423.
44.
Levin M, Gent M, Hirsh J: A comparison of a low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996, 334(11): 677-681.
45.
Young E, Wells P, Holloway S, et al.: Exvivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins that unfractionated heparin. Thromb Haemost. 1994; 71(3): 300-304.
46.
Hirsh J, Warkentin TE, Raschke R, et al.: Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and satiety. Chest. 1998; 114(5): 489S-510S.
47.
Hirsh J, Dalen JE, Anderson DR, et al.: Chest. 1998; 114(5): 445S-469S.
48.
Decousus H, Leizorovicz A, Parent F, et al.: N Engl J Med. 1998; 338(7): 409-415.
49.
Decousus H, Julliard-Delsart D, Mismetti P: Current indications of cava filters. Rev Med Interne. 1997; 18(suppl. 6): 646S-650S.
50.
American College of Chest Physicians: Algorithm for Antigoagulation: LMWH. In Schunemann H (ed.): Sixth ACCP Consensus Conference on Antithrombotic Therapy: Quick Reference Guide for Clinicians. Dupont Pharmaceuticals, 2001.
51.
Levine MN, Raskob G, Landefeld S, et al.: Hemorrhagic complications of anticoagulant treatment. Chest. 1998, 114(suppl. 5): 511S-23S.
52.
Rosen PJ: Bleeding problems in the cancer patient. Hematol Oncol Clin North Am. 1992; 6(6): 1315-1328.
53.
Bick RL, Strauss JF, Frenkel EP: Thrombosis and hemorrhage in oncology patients. Hematol Oncol Clin North Am. 1996; 10(4): 875-907.
54.
Frenkel EP, Bick R: Issues of thrombosis and hemorrhagic events in patients with cancer. In Vivo. 1998, 12(6): 625-628.
55.
Janssens AM, Offner FC, Van Hove WZ: Bone marrow necrosis. Cancer. 2000; 88(8): 1769-1780.
56.
Elliott M, Nichols WL: Thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Mayo Clin Proc. 2001; 76(11): 1154-1162.
57.
Jelkmann W: The role of the liver in the production of thrombopoietin compared with erythropoietin. Eur J Gastroenterol Hepatol. 2001; 13(7): 791-801.
58.
George JN, Raskob GE, Shah SR, et al.: Drug-induced thrombocytopenia: A systemic review of published case reports. Ann Intern Med. 1998; 129(11): 886-890.
59.
Gordon LI, Kwaan HC: Thrombotic microangiopathy manifestin as thrombotic thrombocytopenic purpura/hemolytic uremic syndrome in the cancer patient. Semin Thromb Hemost. 1999; 25(2): 217-221.
60.
Cines DB, Blanchette VS: Medical progress: immune thrombocytopenic purpura. N Engl J Med. 2002; 346(13): 995-1008.
61.
Vincent JL, Yagushi A, Pradier O: Platelet function in sepsis. Crit Care Med. 2002; 30(5): S313-S317.
62.
White B, Perry D: Acquired antithrombin deficiency in sepsis. Br J Haematol. 2001; 112(1): 26-31.
